Country: Canada
Language: English
Source: Health Canada
VALPROIC ACID (DIVALPROEX SODIUM)
PHARMEL INC
N03AG01
VALPROIC ACID
125MG
TABLET (ENTERIC-COATED)
VALPROIC ACID (DIVALPROEX SODIUM) 125MG
ORAL
100
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0112996004; AHFS:
CANCELLED POST MARKET
2016-10-25
PRODUCT MONOGRAPH PR PHL-DIVALPROEX (Divalproex Sodium USP) Enteric-Coated Tablets (125 mg, 250 mg, 500 mg) Antiepileptic PHARMEL INC. 6111 Royalmount Ave., Suite 100 Montreal, Quebec H4P 2T4 Date of Revision: February 22, 2013 Submission Control No: 162202 _phl-DIVALPROEX Product Monograph _ _Page 2 of 51_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................16 DRUG INTERACTIONS ..................................................................................................22 DOSAGE AND ADMINISTRATION ..............................................................................29 OVERDOSAGE ................................................................................................................32 ACTION AND CLINICAL PHARMACOLOGY ............................................................32 STORAGE AND STABILITY ..........................................................................................35 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................35 PART II: SCIENTIFIC INFORMATION ...............................................................................37 PHARMACEUTICAL INFORMATION ..........................................................................37 CLINICAL TRIALS ..........................................................................................................38 DETAILED PHARMACOLOGY ................................................ Read the complete document